Telix Pharmaceuticals Receives FDA Approval for Brain Cancer Imaging Drug Pixclara

07:14 AM EDT, 09/14/2026 (MT Newswires) -- Telix Pharmaceuticals (TLX) received approval from the US Food and Drug Administration for its new drug application for Pixclara, an amino acid positron emission tomography drug for brain cancer. Telix said PET imaging with floretyrosine F 18 is recommended in international clinical practice guidelines for glioma imaging, including the NCCN Guidelines. Shares of the company were up more than 5% in premarket trading Monday.